Table 1.
Participant characteristics
| Oncology patients (Vaccinated) | HD (vaccinated) | SARS-CoV-2 infection | |||||||||
| Entire cancer cohort | IO | Chemo | Chemo+IO | B cell targeted agents | Targeted therapy or hormonal tx | Not on active tx | Non-IMCD, non-cancer | Cancer | |||
| n=118 | n=38 | n=19 | n=7 | n=18 | n=8 | n=28 | n=22 | n=55 | n=10 | ||
| Age, mean in years (range) | 63 (28–81) | 66 (45–81) | 59 (30–79) | 60 (37–73) | 65 (59–76) | 63 (50–71) | 61 (28–81) | 48 (31–67) | 56 (31->90) | 62 (36–76) | |
| Male sex, n (%) | 56 (47%) | 13 (34%) | 9 (47%) | 4 (50%) | 10 (56%) | 6 (75%) | 14 (50%) | 10 (45%) | 31 (56%) | 4 (40%) | |
| Race, n (%) | |||||||||||
| African-American | 20 (17%) | 7 (18%) | 6 (32%) | 1 (14%) | 2 (11%) | 1 (13%) | 3 (11%) | 0 (0%) | 41 (75%) | 7 (70%) | |
| Caucasian | 91 (77%) | 28 (74%) | 12 (63%) | 6 (86%) | 15 (83%) | 6 (75%) | 24 (86%) | 15 (68%) | 6 (11%) | 2 (20%) | |
| Asian | 2 (2%) | 1 (3%) | 0 (%) | 0 (%) | 1 (6%) | 0 (0%) | 0 (0%) | 6 (27%) | 1 (2%) | 0 (0%) | |
| Did not disclose/more than 1 | 5 (5%) | 2 (5%) | 1 (5%) | 0 (%) | 0 (%) | 1 (13%) | 1 (3.6%) | 1 (5%) | 7 (13%) | 1 (11%) | |
| Vaccine manufacturer, n (%) | |||||||||||
| Pfizer | 101 (86%) | 30 (79%) | 15 (79%) | 7 (100%) | 18 (100%) | 8 (100%) | 23 (82%) | 22 (100%) | N/A | N/A | |
| Moderna | 17 (14%) | 8 (21%) | 4 (21%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (18%) | 0 (0%) | N/A | N/A | |
| Cancer type, n (%) | |||||||||||
| Melanoma or skin | 30 (25%) | 11 (29%) | 3 (16%) | 0 (%) | 1 (6%) | 0 (0%) | 15 (54%) | - | - | 1 (10%) | |
| Thoracic | 24 (20%) | 11 (29%) | 5 (26%) | 4 (57%) | 0 (%) | 2 (25%) | 2 (7%) | - | - | 2 (20%) | |
| GI | 17 (14%) | 5 (13%) | 9 (47%) | 1 (14%) | 0 (%) | 0 (0%) | 2 (7%) | - | - | 0 (0%) | |
| GU | 14 (12%) | 5 (13%) | 2 (11%) | 1 (14%) | 0 (%) | 4 (50%) | 2 (7%) | - | - | 0 (0%) | |
| Head & neck, endocrine | 5 (4%) | 2 (5%) | 0 (%) | 1 (14%) | 0 (%) | 0 (0%) | 2 (7%) | - | - | 1 (10%) | |
| Breast/Gyn | 6 (5%) | 3 (8%) | 0 (%) | 0 (%) | 0 (%) | 1 (13%) | 2 (7%) | - | - | 2 (20%) | |
| Hematological malignancy | 22 (19%) | 1 (3%) | 0 (%) | 0 (%) | 17 (94%) | 1 (13%) | 3 (11%) | - | - | 4 (40%) | |
| Stage, n (%) | |||||||||||
| I or II - on active tx | 4 (3%) | 2 (5%) | 2 (11%) | 0 (%) | 0 (%) | 0 (0%) | 0 (0%) | - | - | - | |
| I or II - previously resected, currently NED | 3 (3%) | 0 (0%) | 0 (%) | 0 (%) | 0 (%) | 0 (0%) | 3 (11%) | - | - | 2 (20%) | |
| III - on active tx | 11 (9%) | 4 (11%) | 4 (21%) | 3 (43%) | 0 (%) | 0 (0%) | 0 (0%) | - | - | 1 (10%) | |
| III - previously resected, currently NED | 6 (5%) | 0 (0%) | 0 (%) | 0 (%) | 0 (%) | 1 (13%) | 5 (18%) | - | - | - | |
| IV | 71 (60%) | 31 (82%) | 13 (68%) | 4 (57%) | 0 (%) | 6 (75) | 17 (61%) | - | - | 1 (10%) | |
| Non-TNM staging or NR | 23 (20%) | 1 (3%) | 0 (%) | 0 (%) | 18 (100%) | 1 (13%) | 3 (11%) | - | - | 6 (60%) | |
| ECOG PS, n (%) | |||||||||||
| 0 | 73 (62%) | 16 (42%) | 10 (53%) | 3 (43%) | 15 (83%) | 7 (88%) | 22 (79%) | - | - | 3 (30%) | |
| 1 | 37 (31%) | 19 (50%) | 7 (37%) | 4 (57%) | 3 (17%) | 0 (0%) | 4 (14%) | - | - | 4 (40%) | |
| 2 | 8 (7%) | 3 (8%) | 2 (11%) | 0 (%) | 0 (%) | 1 (13%) | 2 (7%) | - | - | 2 (20%) | |
| NR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 1 (10%) | |
| SARS-CoV-2 infection prior to vaccination | 12 (10%) | 2 (5%) | 3 (16%) | 1 (14%) | 4 (22%) | 1 (13%) | 1 (4%) | 0 (0%) | - | - | |
| Received steroids within a week of vaccine, n (%) | 22 (19%) | 0 (0%) | 12 (63%) | 3 (43%) | 7 (39%) | 0 (0%) | 0 (0%) | - | - | - | |
| Average WCC prior to first vaccination | 6.6 | 9.3 | 4.9 | 7.9 | 6 | 5.9 | - | - | - | ||
Antibody titers after vaccination were evaluated in 117 patients with cancer and 22 HDs, and after infection in 65 unvaccinated patients. T cell responses after vaccination were evaluated in a subset of 66 patients with cancer and 11 HDs.
ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastrointestinal; GU, genitourinary; Gyn, gynecologic; HD, healthy donors; IMCD, immunocompromised; IO, immunotherapy; NED, no evidence of disease; NR, not reported; Tx, treatment; WCC, white cell count.